ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at A... ( Enrollment completed in separate Pha...)

ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting

Date:10/24/2007

Enrollment completed in separate Phase II study in Carotid Atherosclerosis

LEXINGTON, Mass., Oct. 24 /PRNewswire/ -- ActivBiotics, Inc. today announced that the results of its pivotal clinical trial (PROVIDENCE-1) studying the effect of rifalazil in the treatment of intermittent claudication associated with peripheral arterial disease (PAD) will be presented on November 7, 2007 at 11:45 a.m. EST at a late breaker Scientific Session at the American Heart Association's 2007 annual meeting being held in Orlando, Florida. Michael R. Jaff, DO, FACP, FACC, Assistant Professor of Medicine, Harvard Medical School and Medical Director, Massachusetts General Hospital Vascular Center, Boston, Massachusetts, Chair of the trial's Steering Committee, will be presenting.

PROVIDENCE-1 (Prospective Evaluation of Rifalazil Effect on Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients) is the first of two planned Phase III clinical trials to study the ability of rifalazil to improve symptoms in patients suffering from intermittent claudication, an often debilitating and under diagnosed manifestation of PAD. The prospective, double-blind, randomized, placebo- controlled trial evaluated the efficacy and safety of rifalazil in 297 patients from the United States, Russia and Brazil. The FDA has granted rifalazil Fast Track designation for development in this indication.

In addition to the PROVIDENCE-1 Phase III clinical trial, a Phase II study to evaluate the effect of rifalazil on the progression of carotid artery atherosclerosis has completed its target enrollment of 72 patients. The RESTORE-IT trial (Randomized Evaluation of Short-Term Rifalazil Treatment on Carotid Atherosclerosis and Intima Media Thickness) is a prospective, randomized, double-blind, placebo-controlled, multi-center study of patients with a clinical history of atherosclerosis and image-detectable carotid disease. This study will use the non-inva
'/>"/>

SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:

(Date:5/21/2013)... 2013 Lakeland Industries, Inc. (NASDAQ: ... protective clothing for industry, municipalities, healthcare and first ... today announced that the Company accepted a commitment ... Facility subject to certain terms and conditions and ... no assurances can be given that this transaction ...

(Date:5/21/2013)... 21, 2013 Tom Daulton, CEO of Mammotome, a division ... Year by the Cincinnati chapter of ... by another local top executive who is also a breast ... Ethicon Endo-Surgery in March of 2010. Daulton will be presented ... presented by Huntington Bank, on May 22. The ...

(Date:5/21/2013)... Kepner-Tregoe (KT), the global capability development ... Chris Geraghty has been ... than 20 years serving the industrial sector, holding ... succeeds Ray Baxter , who ... the Board and CEO. (Logo: ...

[0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results [0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year [0] Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer

... 14, 2011 /PRNewswire / -- Nephros, Inc. (OTC Bulletin Board: ... three months ended September 30, 2011. Recent ... associated with Rights Offering to be exercised; Received initial ... Hemodiafiltration System in U.S. Financial ...

... 14, 2011 Landauer, Inc. (NYSE: LDR ... radiation monitoring and the leading domestic provider of outsourced ... all of the outstanding equity interests of IZI Medical ... a purchase price of approximately $93 million. IZI Medical ...

Cached Medicine Technology:Nephros Reports Third Quarter 2011 Financial Results 2 Nephros Reports Third Quarter 2011 Financial Results 3 Nephros Reports Third Quarter 2011 Financial Results 4 Nephros Reports Third Quarter 2011 Financial Results 5 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 2 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 3 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 4 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 5 Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 6

Nephros Reports Third Quarter 2011 Financial Results Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC

(Date:5/21/2013)... CA (PRWEB) May 21, 2013 DISCcert ... materials showing how to use 17 DISC applications at ... is a natural progression. , The July 25 & ... the top 17 ways of applying DISC. The time-tested, ... certified graduates. The user-friendly DISC training materials ...

(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...

(Date:5/21/2013)... The Orsiro stent, which is a novel stent ... non-inferiority to the Xience Prime everolimus-eluting stent for ... loss at nine months in the results of ... , The BIOFLOW-II substudy used intravascular ultrasound (IVUS) ... neointimal hyperplasia and stent apposition at nine months ...

(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...

(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...

Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2

[0] DISCcert Offers 17 Applications in Coming DISC Certification [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Biodegradable stent proves non-inferior to drug-eluting stent [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference [0] Researchers find genetic risk factor for pulmonary fibrosis

... The Lancet Supports Cardio-Protective Potential of Aleglitazar - , ... will start Phase III clinical investigations for aleglitazar, its innovative ... morbidity and mortality in high risk patients with type 2 ... II SYNCHRONY study published today in The Lancet(1) ...

... , Customizable Survival Kit Offers One Stop for ... Local Healthcare Market Drivers and Health Plan Trends ... a leading provider of managed care market intelligence, ... shifts in membership at the state level than ...

... the company that will become public from the planned ... today filed a second amendment to its Form 10 ... that includes information about its post-spin board of directors ... under a consent decree for its Alaris(R) infusion products. ...

... United Spinal Association ( www.UnitedSpinal.org ) presents the ... ) , the region,s premiere lifestyle-enhancing Expo designed to ... aging Americans. , , The Independence Expo will ... at the Suffolk Community College Sports & Exhibition Complex in ...

... PSI-7851 was generally safe and well tolerated in Phase 1a ... results from single ascending and multiple ascending dose trials are ... June 9 Pharmasset, Inc. (Nasdaq: VRUS ) ... study and begun dosing in a multiple ascending dose trial ...

... ... its Multilayer Aneurysm Repair System (MARS) has received CE Mark approval for treating patients ... ... announced today that it has received CE Mark approval for the commercial sale of ...

Cached Medicine News:Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 2 Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 3 Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 4 Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 5 Health News:Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment 2 Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 2 Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 3 Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 4 Health News:United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging 2 Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 2 Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 3 Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 4 Health News:Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms 2

Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment CareFusion Announces Board of Directors, Progress on Alaris Consent Decree United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • Not available with casters • With Tubular Base....

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....

Medicine Products:

4V63 4V61-R 4V42-R 4V58-R